Kiniksa Pharmaceuticals, Ltd. KNSA 深 沪
已收盘 04-02 16:00:00 美东时间
48.82
+0.690
+1.43%
华盛通- 最 高48.85
- 今 开47.75
- 成交量 43.63万股
- 最 低 46.82
- 昨 收 48.13
- 总市值 37.36亿
- 52周最高 49.3294
- 市盈率 静 65.35
- 换手率 0.57%
- 52周最低 19.41
- 委 比 15.55%
- 总股本 7653.54万
- 历史最高 49.3294
- 量 比 0.78
- 振 幅 4.22%
- 历史最低 5.01
- 每 手 1
- 风险率 7.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kiniksa Pharmaceuticals Earnings Call Highlights ARCALYST Surge
Kiniksa Pharmaceuticals Ltd. Class A (($KNSA)) has held its Q4 earnings call. R...
03-11 08:23
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
Kiniksa Pharmaceuticals Q4 Earnings Assessment
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported its Q4 earnings results on Tuesd...
02-24 20:34
Kiniksa Pharmaceuticals Sees FY2026 Sales $900.000M-$920.000M vs $902.168M Est
Kiniksa Pharmaceuticals (NASDAQ:KNSA) sees FY2026 sales of $900.000 million-$920.000 million vs $902.168 million analyst estimate.
02-24 20:33
Kiniksa Pharmaceuticals Q4 EPS $0.17 Misses $0.38 Estimate, Sales $202.127M Beat $195.005M Estimate.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.38 by 54.67 percent. This is a 241.67 percent increase over losses of $(0.12) per
02-24 20:32
Earnings Scheduled For February 24, 2026
Companies Reporting Before The Bell • China Yuchai Intl (NYSE:CYD) is expected ...
02-24 19:11
美股大行评级 | 潜在涨幅108.69%！Stephens & Co.维持圣玛丽石油勘测"超配"评级，上调目标价至49美元
今日重点评级关注：Stephens & Co.：维持圣玛丽石油勘测"超配"评级，目标价从48美元升至49美元；花旗：维持IDEAYA Biosciences"买入"评级，目标价从64美元升至65美元
02-20 15:57
Canaccord Genuity Initiates Coverage On Kiniksa Pharmaceuticals with Buy Rating, Announces Price Target of $62
Canaccord Genuity analyst Edward Nash initiates coverage on Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy rating and announces Price Target of $62.
02-19 21:31
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Kiniksa Pharmaceuticals International, plc will host a conference call/webcast on Feb.24, 2026 at 8:30 a.m. EST to discuss 4th quarter and full year 2025 financial results and recent portfolio execution. The live webcast is accessible via the company’s website, and individuals can register for the call here. A replay will be available on the website within 48 hours. Kiniksa is a biopharmaceutical company focused on developing therapies for diseas...
02-19 21:01
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
